New guidance standardizes how cardiac risk data should be evaluated and presented in prescription drug labeling
The U.S. Food and Drug Administration (FDA) has published guidance titled QTc Information in Human Prescription Drug and Biological Product Labeling (December 2025), outlining how sponsors should evaluate and communicate the potential for QTc interval prolongation in prescription drug labeling.
QTc interval prolongation reflects a delay in cardiac repolarization, which can be measured using an electrocardiogram (ECG). In some cases, this delay may increase the risk of serious arrhythmias, including torsade de pointes, ventricular fibrillation, and sudden death.
The guidance applies to non-antiarrhythmic prescription drugs with systemic bioavailability and is focused not only on identifying risk, but on ensuring that clinically relevant information is consistently and clearly presented across U.S. Prescribing Information (USPI).
What the FDA is recommending
The FDA recommends that sponsors assess a drug’s potential to affect cardiac repolarization early in clinical development. This typically includes clinical electrocardiographic evaluation to characterize any impact on the QTc interval.
A key focus of the guidance is how QTc-related findings should be incorporated into labeling. Rather than simply including the information, the FDA outlines where and how it should appear within the USPI. Depending on the level of risk and available data, this may include:
- Clinical Pharmacology sections describing the drug’s effect on cardiac electrophysiology, including when clinically meaningful QTc prolongation is not observed
- Warnings and Precautions when QTc prolongation represents a clinically significant safety concern
- Drug Interactions sections addressing concomitant use with other products that either prolong the QTc interval or increase exposure to the subject drug
- Dosage and Administration recommendations, including potential dose adjustments and ECG monitoring
In more serious cases, QTc-related risks may also warrant inclusion in boxed warnings or patient-facing labeling such as Medication Guides.
Additional considerations from the guidance
The FDA notes that QTc interval prolongation is an imperfect predictor of proarrhythmic risk. However, because of its established relationship to serious cardiac events, the agency continues to rely on QTc data as an important safety signal.
The guidance also emphasizes that the absence of observed arrhythmic events in clinical trials does not necessarily indicate the absence of risk. As a result, labeling decisions should consider the totality of evidence, including pharmacologic properties, exposure levels, and known interactions.
Concomitant drug use is highlighted as a key risk factor. Products that independently prolong the QTc interval or increase drug concentrations may significantly elevate overall risk when used together, and this interaction should be clearly communicated in labeling.
It is also important to note that this guidance reflects the FDA’s current thinking and does not establish legally enforceable requirements.
Why this matters for importers
While this guidance is directed at drug sponsors, it has downstream implications for importers, distributors, and supply chain stakeholders involved in pharmaceutical and biological products.
Changes to labeling expectations can affect:
- Product approval timelines and regulatory review outcomes
- Documentation and compliance requirements for imported products
- Risk classification and handling considerations across the supply chain
- Due diligence when sourcing or evaluating pharmaceutical products for the U.S. market
As FDA continues to standardize how safety information is presented, companies involved in importing or distributing drug products should be aware of how these updates may influence product labeling and regulatory expectations.
For more information, refer to the FDA guidance.
If you have questions about how regulatory changes may impact your imports, contact the Alba team.
